Скачать или смотреть Prof. Nawamin Pinpathomrat: Preclinical study of TB vaccine development using viral vector and mRNA

Prof. Nawamin discusses on the preclinical development of tuberculosis vaccines using Viral vector and mRNA platforms, inspired by the success of mixed COVID-19 vaccine regimens to enhance immune responses. The team identified promising TB antigens through immune stimulation and mass spectrometry, with some, like IrA, showing strong immunogenicity in mice. They tested different antigen combinations and sequences using in silico modeling to optimize T cell and TH1 responses before moving to animal studies, aiming to boost both antibody and cellular immunity. The ultimate goal is to combine BCG priming with Viral vector and mRNA boosters to improve protection against TB.

Biography:
Prof. Nawamin Pinpathomrat is a physician-scientist specializing in immunology and vaccine development. He received his M.D. from Prince of Songkla University, Thailand, where he leads translational research focused on host-pathogen interactions and immune responses to Mycobacterium tuberculosis.

Prof. Pinpathomrat’s work centres on the design and evaluation of novel vaccine candidates, with particular emphasis on mRNA-based and viral vector platforms. His research integrates molecular biology, cellular immunology, and experimental model development to advance next-generation tuberculosis vaccines.

In addition to his research activities, Prof. Pinpathomrat is actively involved in academic mentorship and institutional development, including the establishment of biosafety level 3 (BSL-3) laboratory infrastructure to support preclinical tuberculosis studies. His interdisciplinary approach contributes to innovations in TB vaccine research and translational immunology.